ArticleEuropean journal of pediatrics2026
Autoimmune and lymphoproliferative outcomes after Kawasaki disease: a 20-year population-based cohort study.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD) is an acute systemic vasculitis of childhood associated with profound immune dysregulation that may persist beyond the acute inflammatory phase. The long-term risks of autoimmune diseases and lymphoproliferative malignancies in children with KD remain incompletely defined. To determine whether children with KD carry increased 20-year risks of autoimmune and lymphoproliferative outcomes compared with matched controls. We conducted a retrospective matched cohort study using the Clalit Health Services database (2002-2022). Children with KD (n = 2,126) were matched 1:5 to controls (n = 10,630) by sex and birthdate (± 30 days) and followed through December 2024. Outcomes comprised psoriasis, vitiligo, hypothyroidism, type 1 diabetes mellitus (T1DM), celiac disease, inflammatory bowel disease (IBD), immune thrombocytopenia (ITP), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL). Adjusted hazard ratios (AHRs) with 95% confidence intervals were estimated using Cox proportional hazards models at 2, 5, 10, 15, and 20 years. KD was associated with a significantly increased risk of psoriasis from 2 years (AHR 3.03, 95% CI 1.19-7.73) through 15 years (AHR 1.50, 95% CI 1.01-2.23), attenuating to non-significance at 20 years. Vitiligo reached statistical significance at 10 years (AHR 1.38, 95% CI 1.03-1.86). A nominally significant elevation in HL risk was observed from 15 years onward (AHR 14.99, 95% CI 1.55-145.12, at 15 years; AHR 7.95, 95% CI 1.32-48.00, at 20 years); however, these estimates are based on three events in the KD group versus one to two in controls, yielding confidence intervals spanning nearly two orders of magnitude, and must be interpreted as exploratory signals only. No significant associations were found for hypothyroidism, T1DM, ITP, celiac disease, IBD, or NHL.
conclusionKD was associated with a sustained increase in psoriasis risk and a consistent trend toward increased vitiligo risk, reaching statistical significance at 10 years. An exploratory HL signal emerged during long-term follow-up but was based on very few events. Overall, these findings support selective long-term immune dysregulation following KD and highlight the importance of dermatologic awareness during long-term follow-up. WHAT IS KNOWN: • Kawasaki disease (KD) causes profound immune dysregulation that may persist beyond the acute phase. • Whether KD increases long-term risks of autoimmune and lymphoproliferative disease remains unclear. WHAT IS NEW: • Over 20 years, KD was associated with sustained psoriasis risk and a significant rise in vitiligo risk at 10 years. • No increased risk was found for hypothyroidism, type 1 diabetes, celiac disease, IBD, or ITP, indicating selective rather than generalized immune dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.